1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Cian Healthcare Limited

Cian Healthcare Limited

BBSE:CHCL
29.77
INR
+0.58
(+1.99%)
171.84MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
291.3
323.13
370.77
389.64
355.94
404.81
453.35
399.05
360.33
12.32
11.32
- -
Basic EPS, GAAP
8.56
13.96
24.99
4.09
-23.62
0.29
-32.22
11.81
4.96
-10.39
-9.32
- -
Free Cash Flow per Basic Share
56.73
7.97
30.04
42.86
-167.82
24.5
-50.88
20.46
62.99
8.14
-0.92
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
67.43
81.39
110.7
135.42
363.11
363.44
323.42
335.25
340.2
12.95
49.77
49.77
Tangible Book Value per Share
65.28
79.93
110.01
135.42
332.61
363.44
323.42
335.25
340.2
12.95
49.77
49.77
Basic Weighted Avg Shares
2
2
2
2
2
2
2
2
2
25
25
25
Sales/Revenue/Turnover
467
518
594
624
571
737
779
686
617
308
283
- -
Operating Margin (%)
12.13
15.73
18.56
9.48
5.5
11.86
0.36
11.14
9.4
-35.45
-35.97
- -
Depreciation Expense
19
19
14
24
44
35
43
54
55
44
39
- -
Net Income, GAAP
14
22
40
7
-38
1
-55
20
8
-260
-233
- -
Effective Tax Rate (%)
36.49
27.36
23.86
30.35
- -
92.27
- -
- -
- -
- -
- -
- -
Profit Margin (%)
2.94
4.32
6.74
1.05
-6.63
0.07
-7.11
2.96
1.38
-84.35
-82.31
- -
Working Capital
25
64
107
75
58
56
95
90
56
-437
-63
-63
LT Debt
204
240
246
229
458
376
381
294
275
69
202
202
Total Equity
108
130
177
217
582
582
555
575
583
324
85
85
Return on Invested Capital (%)
- -
11.99
13.46
5.55
- -
0.51
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
12.07
13.41
6.36
- -
0.49
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
18.75
26.02
3.32
-9.48
0.09
-9.73
3.59
1.47
-57.29
-113.92
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
481
396
85
LT Borrowings
69
4
202
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
6
8
172

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
708
610
229
Cash, Cash Equivalents & STI
178
107
12
Accounts Receivable, Net
174
179
126
Inventories
261
230
50
Total Current Liabilities
1,145
943
292
Payables & Accruals
- -
- -
- -
ST Debt
481
396
85
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.95%
-23.56%
-73.62%
Free Cash Flow
-62.7%
-50.4%
-111.27%
Net Income, GAAP
-1,460.86%
-2,777.51%
-10.34%
Sales/Revenue/Turnover
-2.32%
-14.91%
-8.12%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
617
2025
- -
- -
308
2026
- -
- -
283

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4.96
2025
- -
- -
-10.39
2026
- -
- -
-9.32

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rajesh Jain
Full Time Employees
170
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Office No 301, Konark Icon Pune India 411028
IPO Date
May 23, 2019
Website
cian.co
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Cian Healthcare Limited (CHCL.BO) is an India-based pharmaceutical company engaged in the manufacturing and marketing of generic and branded formulations across various therapeutic segments. The company offers a diverse portfolio of products including tablets, capsules, injectables, ointments, and powders; key categories encompass anti-infectives, analgesics, anti-diabetics, cardiovascular drugs, gastro-intestinal treatments, and nutraceuticals, marketed under brands such as Cianpro, Ciangrow, and Cianfit. It primarily serves retail pharmacies, hospitals, and institutional customers in India, with distribution networks spanning major regions including Maharashtra, Gujarat, Uttar Pradesh, and emerging markets in South India. Founded in 2015 and headquartered in Mumbai, India, Cian Healthcare operates manufacturing facilities compliant with WHO-GMP standards, focusing on affordable healthcare solutions for chronic and acute conditions. The company targets middle-income consumers and government tenders, emphasizing quality generics and value-added services like contract manufacturing. Its business segments include domestic formulations, exports to select Asian and African countries, and a growing nutraceutical division. In recent developments, Cian Healthcare expanded its product pipeline with the launch of five new anti-diabetic combinations and two oncology injectables in 2024, strengthening its chronic therapy portfolio. The company secured a strategic distribution partnership with a leading South Indian pharma distributor in early 2025 to boost market penetration in Tamil Nadu and Karnataka. Additionally, it raised INR 50 crore through a preferential allotment in Q3 2025 to fund capacity expansion and R&D for complex generics.